Biopharmaceuticals - Quality Development and Documentation, module 10

Get an understanding of the quality issues specific to biopharmaceuticals

5 - 7 Dec 2023

or

25 - 27 Nov 2024

On location

English

21,730 DKK ex VAT

(app. 2,922 EUR ex VAT)

Summary

Module 10 

This module will teach you about the scientific background of biologics and biotechnological products as well as which regulatory requirements you need to fulfil in order to obtain approval for these types of medicinal products. 
You will get an understanding of the quality issues specific to biopharmaceuticals. As process changes are inevitable during the development of a biological/biotechnological product, this course will teach you about the implications of changes in the production process and elaborate on the concept of comparability. 

You will also learn how to prepare regulatory (CMC)  and quality strategies as well as how to ensure that you are compliant with regulatory requirements throughout the clinical development and post-approval processes. Our discussions on CMC/Quality strategies will include both FDA and EU aspects as well as FDA and EU regulatory procedures for approval.


Other course participants say:

"The course has provided me with a very good overview and understanding on the regulatory CMC requirements for development of biologics." 

Helene Mortensen, Principal Scientist, Biopharmaceutical Product Development, CMC, LEO Pharma A/S


Keywords

  • Biopharmaceuticals
  • Chemistry, Manufacturing and Controls (CMC)
  • Regulatory CMC strategies
  • Quality Sections for IND/CTA and BLA/NDA /MAA
  • Product Comparability
  • Biosimilars
  • Product Characterization and Specification
  • Quality Regulatory Compliance Strategy
  • EU and FDA Regulatory Procedures for Biotech Products

    Hi! 

    Do you need help choosing the right course? 

    We are ready to help you at +45 39 27 60 60 or contact@atriumcph.com 

    Stay tuned with Atrium's newsletter 


Please note: 

As this module is a mandatory module in the Master of Medicines Regulatory Affairs at the University of Copenhagen you will apply via the joint Atrium and University of Copenhagen application form. This means that you will be enrolled at both Atrium and the University of Copenhagen and that your data will be registered at both institutions. If you are not enrolled as a master student, you will be registered as a single course student at the University of Copenhagen.

Course fee includes examination. By default you will pay the full amount to the University of Copenhagen regardless of you taking the exam or not. If you decide not to take the exam, you can apply for a refund of the exam fee at Atrium by contacting Atrium - please see contact details below. You must apply for a refund no later than two weeks after completion of the course.


Save information for later
Read more

Course leader & lecturers

  • Sandra Auguste-Bowler
    Course leader
    Principal regulatory specialist
    Novo Nordisk A/S
  • Heidi Smed Christensen
    Course leader
    Senior Director, Regulatory Affairs
    Genmab A/S
  • Allan Hey
    Lecturer
    CMC Consultant, Manangara Ltd
    Atrium
  • Anne Kroll Kristensen
    Lecturer
    Principal Scientist
    Novo Nordisk A/S
  • Lisbeth Palm
    Lecturer
    Senior Project Manager
    Novo Nordisk A/S
  • Anna Karin Rehnström
    Lecturer
    Manager Biotechnology
    Swedish Medicines Products Agency - MPA
  • Steffen Gross
    Lecturer
    Head of Section Quality and Non-Clinical Evaluation of Antibody Therapeutics
    Paul-Ehrlich-Institut (PEI)
  • Margrethe Erbou Andersen
    Lecturer
    VP Regulatory Affairs
    Galecto Biotech AB
  • Asser Sloth Andersen
    Lecturer
    Senior Principal Scientist
    Novo Nordisk A/S
  • Maria Wahlbom
    Lecturer
    Senior Manager, CMC RA
    Genmab A/S
  • Nanna Aaby Thirstrup
    Lecturer
    Director of Division, Quality Assessment & Clinical Trials
    Danish Medicines Agency
  • Jens Christian Wortmann
    Lecturer
    Project Director - Cell Therapy CMC & Manufacturing
    Novo Nordisk A/S
  • Stacy Plum
    Lecturer
    Vice President, PhD, Head of Biologics
    Syner-G BioPharma
See all

Is this course for you?

This course is for you if you work as a regulatory affairs specialist, employed in the industry, a regulatory agency, or a consulting firm.

You must have a minimum of 2 years relevant job experience.

What you will learn

  1. The basic principles of manufacturing biopharmaceuticals — from the recombinant starting material to the final product
  2. How to evaluate and organize information provided by CMC/quality stakeholders during product development and post-approval
  3. How to prepare regulatory CMC/quality strategies considering both FDA and EU aspects throughout clinical development and how to evaluate relevant regulations and guidelines for biopharmaceuticals
  4. How to use best practice in product characterization and how to set the release and stability specifications of a biopharmaceutical

What your company will get

  1. A regulatory professional who understands the basic principles of manufacturing biopharmaceuticals
  2. A regulatory affairs professional who is able to evaluate and organize the information and documentation provided by CMC/Quality stakeholders, challenge it and ask the right questions
  3. A regulatory affairs professional who is able to prepare regulatory CMC/Quality strategies considering both FDA and EU aspects

Course calendar

Choose your starting date
Starting 5 Dec 2023
Starting 25 Nov 2024
5 Dec 2023 8:15-17:45

Day 1

  • Why the regulatory agencies treat biopharmaceuticals differently than chemical pharmaceuticals
  • CMC/Quality sections for IND/CTA and BLA/NDA/MAA in CTD format including electronic submission to FDA as eCTD
  • Generation of the recombinant construct, cell banks and expression
  • Stability studies for drug substance and drug product
  • Purification and process validation
  • Group work
6 Dec 2023 8:15-17:20

Day 2

  • Formulation development and drug product manufacturing
  • Demonstrating product comparability during development and post-approval
  • Biosimilars
  • Regulatory expectations for product characterization
  • Setting a product specification for drug substance and drug product
  • Group work
7 Dec 2023 8:15-16:30

Day 3

  • Key elements necessary for a complete quality regulatory compliance strategy
  • FDA regulatory procedures for biotech products
  • EU regulatory procedures for biotech products
  • Regulatory CMC strategies in the EU during development
  • Group work
Practical information

Registration

Registration deadline
24 Oct 2023
Atrium
Lersø Parkallé 101
2100 København Ø
Register
5 - 7 Dec
25 Nov 2024 9:00-16:00

Day 1

  • Why the regulatory agencies treat biopharmaceuticals differently than chemical pharmaceuticals
  • CMC/Quality sections for IND/CTA and BLA/NDA/MAA in CTD format including electronic submission to FDA as eCTD
  • Generation of the recombinant construct, cell banks and expression
  • Stability studies for drug substance and drug product
  • Purification and process validation
  • Group work
26 Nov 2024 9:00-16:00

Day 2

  • Formulation development and drug product manufacturing
  • Demonstrating product comparability during development and post-approval
  • Biosimilars
  • Regulatory expectations for product characterization
  • Setting a product specification for drug substance and drug product
  • Group work
27 Nov 2024 9:00-16:00

Day 3

  • Key elements necessary for a complete quality regulatory compliance strategy
  • FDA regulatory procedures for biotech products
  • EU regulatory procedures for biotech products
  • Regulatory CMC strategies in the EU during development
  • Group work
Practical information

Registration

Registration deadline
14 Oct 2024
Atrium
Lersø Parkallé 101
2100 København Ø
Register
25 - 27 Nov
Sometimes things change. This is the expected programme.

Course information

Literature

Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.

Please familiarize yourself with the mandatory readings before starting the course.

The mandatory readings are also part of the examination syllabus. 

Prerequisites

To enroll in this course, you must have a relevant educational background at bachelor level and, as a minimum, two years of experience in regulatory affairs, or other equivalent qualifications. We consider all applications upon registration.

If you do not fulfill the requirements, you can still apply for the course if you have experience in the pharmaceutical/biological area that would allow you to benefit from the training and enable you to participate actively during the module. Up to 20% of the positions on our course are filled by applicants who have no or limited experience in regulatory affairs. We consider applicants on a case-by-case basis.

Examination

The exam is usually held 4-6 weeks after the course.

It is a digital exam in the University of Copenhagen’s digital exam system.

This course is a part of a diploma

Master of Medicines Regulatory Affairs (MRA)

Are you a Regulatory Affairs professional and are you concerned with your ongoing learning and development? Consider these courses, offered in together with University of Copenhagen. Explore the Master of Medicines Regulatory Affairs (MRA).

Read more
Diploma in Regulatory Affairs

The regulatory affairs diploma gives you an understanding of the entire regulatory affairs platform of the medicinal lifecycle. All courses have been designed in collaboration with highly acclaimed experts that are on our regulatory affairs Advisory Board.

Read more

Course leaders

Sandra Auguste-Bowler
Principal regulatory specialist
Novo Nordisk A/S
Heidi Smed Christensen
Senior Director, Regulatory Affairs
Genmab A/S

Lecturers

Sandra Auguste-Bowler
Principal regulatory specialist
Novo Nordisk A/S
Allan Hey
CMC Consultant, Manangara Ltd
Atrium
Anne Kroll Kristensen
Principal Scientist
Novo Nordisk A/S
Lisbeth Palm
Senior Project Manager
Novo Nordisk A/S
Anna Karin Rehnström
Manager Biotechnology
Swedish Medicines Products Agency - MPA
Steffen Gross
Head of Section Quality and Non-Clinical Evaluation of Antibody Therapeutics
Paul-Ehrlich-Institut (PEI)
Margrethe Erbou Andersen
VP Regulatory Affairs
Galecto Biotech AB
Asser Sloth Andersen
Senior Principal Scientist
Novo Nordisk A/S
Heidi Smed Christensen
Senior Director, Regulatory Affairs
Genmab A/S
Maria Wahlbom
Senior Manager, CMC RA
Genmab A/S
Nanna Aaby Thirstrup
Director of Division, Quality Assessment & Clinical Trials
Danish Medicines Agency
Jens Christian Wortmann
Project Director - Cell Therapy CMC & Manufacturing
Novo Nordisk A/S
Stacy Plum
Vice President, PhD, Head of Biologics
Syner-G BioPharma

You may also be interested in these courses

Want to know more or need help?

Contact Client Manager Mette Ribergaard Rasmussen at +45 39 15 09 30

Send me a message